Journal of Peking University(Health Sciences) >
A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies
Received date: 2023-09-04
Online published: 2024-04-10
Objective: To investigate the correlation factors of complete clinical response in idiopathic inflammatory myopathies (IIMs) patients receiving conventional treatment. Methods: Patients diagnosed with IIMs hospitalized in Peking University People's Hospital from January 2000 to June 2023 were included. The correlation factors of complete clinical response to conventional treatment were identified by analyzing the clinical characteristics, laboratory features, peripheral blood lymphocytes, immunological indicators, and therapeutic drugs. Results: Among the 635 patients included, 518 patients finished the follow-up, with an average time of 36.8 months. The total complete clinical response rate of IIMs was 50.0% (259/518). The complete clinical response rate of dermatomyositis (DM), anti-synthetase syndrome (ASS) and immune-mediated necrotizing myopathy (IMNM) were 53.5%, 48.9% and 39.0%, respectively. Fever (P=0.002) and rapid progressive interstitial lung disease (RP-ILD) (P=0.014) were observed much more frequently in non-complete clinical response group than in complete clinical response group. The aspartate transaminase (AST), lactate dehydrogenase (LDH), D-dimer, erythrocyte sedimentation rate (ESR), C-reaction protein (CRP) and serum ferritin were significantly higher in non-complete clinical response group as compared with complete clinical response group. As for the treatment, the percentage of glucocorticoid received and intravenous immunoglobin (IVIG) were significantly higher in non-complete clinical response group than in complete clinical response group. Risk factor analysis showed that IMNM subtype (P=0.007), interstitial lung disease (ILD) (P=0.001), eleva-ted AST (P=0.012), elevated serum ferritin (P=0.016) and decreased count of CD4+T cells in peripheral blood (P=0.004) might be the risk factors for IIMs non-complete clinical response. Conclusion: The total complete clinical response rate of IIMs is low, especially for IMNM subtype. More effective intervention should be administered to patients with ILD, elevated AST, elevated serum ferritin or decreased count of CD4+T cells at disease onset.
Zhanhong LAI , Jiachen LI , Zelin YUN , Yonggang ZHANG , Hao ZHANG , Xiaoyan XING , Miao SHAO , Yuebo JIN , Naidi WANG , Yimin LI , Yuhui LI , Zhanguo LI . A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies[J]. Journal of Peking University(Health Sciences), 2024 , 56(2) : 284 -292 . DOI: 10.19723/j.issn.1671-167X.2024.02.013
| 1 | Tanboon J , Nishino I . Classification of idiopathic inflammatory myopathies: Pathology perspectives[J]. Curr Opin Neurol, 2019, 32 (5): 704- 714. |
| 2 | DeWane ME , Waldman R , Lu J . Dermatomyositis: Clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82 (2): 267- 281. |
| 3 | 罗澜, 邢晓燕, 肖云抒, 等. 抗合成酶综合征合并心脏受累患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2021, 53 (6): 1078- 1082. |
| 4 | Marco JL , Collins BF . Clinical manifestations and treatment of antisynthetase syndrome[J]. Best Pract Res Clin Rheumatol, 2020, 34 (4): 101503. |
| 5 | Pinal-Fernandez I , Casal-Dominguez M , Mammen AL . Immune-mediated necrotizing myopathy[J]. Curr Rheumatol Rep, 2018, 20 (4): 21. |
| 6 | Wolstencroft PW , Chung L , Li S , et al. Factors associated with clinical remission of skin disease in dermatomyositis[J]. JAMA Dermatol, 2018, 154 (1): 44- 51. |
| 7 | Lundberg IE , Fujimoto M , Vencovsky J , et al. Idiopathic inflammatory myopathies[J]. Nat Rev Dis Primers, 2021, 7 (1): 86. |
| 8 | Bohan A , Peter JB . Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292 (7): 344- 347. |
| 9 | Bohan A , Peter JB . Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292 (8): 403- 407. |
| 10 | Lundberg IE , Tj?rnlund A , Bottai M , et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Arthritis Rheumatol, 2017, 69 (12): 2271- 2282. |
| 11 | Allenbach Y , Mammen AL , Benveniste O , et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016[J]. Neuromuscul Disord, 2018, 28 (1): 87- 99. |
| 12 | Oddis CV , Rider LG , Reed AM , et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies[J]. Arthritis Rheum, 2005, 52 (9): 2607- 2615. |
| 13 | Aggarwal R , Rider LG , Ruperto N , et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative[J]. Ann Rheum Dis, 2017, 76 (5): 792- 801. |
| 14 | Tiniakou E , Mecoli CA , Kelly W , et al. Anti-MDA5-positive dermatomyositis and remission in a single referral centre population[J]. Clin Exp Rheumatol, 2023, 41 (2): 309- 315. |
| 15 | Rider LG , Werth VP , Huber AM , et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), myositis functional index-2 (FI-2), myositis activities profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI)[J]. Arthritis Care Res (Hoboken), 2011, 63 (Suppl 11): S118- S157. |
| 16 | Li Y , Li Y , Wu J , et al. Predictors of Poor Outcome of Anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis[J]. J Immunol Res, 2020, 2020, 2024869. |
| 17 | Sultan SM , Ioannou Y , Moss K , et al. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality[J]. Rheumatology (Oxford), 2002, 41 (1): 22- 26. |
| 18 | Lee JS , Lee JE , Hong S , et al. Prognostic factors for steroid-free remission in patients with idiopathic inflammatory myopathies: Importance of anthropometric measurements[J]. Ther Adv Musculoskelet Dis, 2020, 12, 1759720x20936822. |
| 19 | Watanabe E , Gono T , Kuwana M , et al. Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis[J]. Rheumatology (Oxford), 2020, 59 (3): 586- 593. |
| 20 | Mariampillai K , Granger B , Amelin D , et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoanti-bodies[J]. JAMA Neurol, 2018, 75 (12): 1528- 1537. |
| 21 | Watanabe Y , Uruha A , Suzuki S , et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy[J]. J Neurol Neurosurg Psychiatry, 2016, 87 (10): 1038- 1044. |
| 22 | Merlonghi G , Antonini G , Garibaldi M . Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge[J]. Autoimmun Rev, 2022, 21 (2): 102993. |
| 23 | 杨红霞, 田小兰, 江薇, 等. 免疫介导坏死性肌病的临床和病理特征分析[J]. 北京大学学报(医学版), 2019, 51 (6): 989- 995. |
| 24 | Tiniakou E , Pinal-Fernandez I , Lloyd TE , et al. More severe disease and slower recovery in younger patients with anti-3-hydro-xy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy[J]. Rheumatology (Oxford), 2017, 56 (5): 787- 794. |
| 25 | Day JA , Limaye V . Immune-mediated necrotising myopathy: A critical review of current concepts[J]. Semin Arthritis Rheum, 2019, 49 (3): 420- 429. |
| 26 | Redondo-Benito A , Curran A , Villar-Gomez A , et al. Opportunistic infections in patients with idiopathic inflammatory myopathies[J]. Int J Rheum Dis, 2018, 21 (2): 487- 496. |
| 27 | Sun S , Chen Z , Zhang D , et al. Description and analysis of a novel subtype of the anti-synthetase syndrome characterized by frequent attacks of fever and systemic inflammation in a single-center cohort study[J]. Front Immunol, 2021, 12, 729602. |
| 28 | Debray MP , Borie R , Revel MP , et al. Interstitial lung disease in anti-synthetase syndrome: Initial and follow-up CT findings[J]. Eur J Radiol, 2015, 84 (3): 516- 523. |
| 29 | Hallowell RW , Ascherman DP , Danoff SK . Pulmonary manifestations of polymyositis/dermatomyositis[J]. Semin Respir Crit Care Med, 2014, 35 (2): 239- 248. |
| 30 | 李玉慧, 姚海红, 张学武, 等. 94例皮肌炎患者器官受累及免疫学特征分析[J]. 北京大学学报(医学版), 2010, 42 (2): 140- 142. |
| 31 | Johnson C , Pinal-Fernandez I , Parikh R , et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease[J]. Lung, 2016, 194 (5): 733- 737. |
| 32 | Chen IJ , Wu YJJ , Lin CW , et al. Interstitial lung disease in polymyositis and dermatomyositis[J]. Clin Rheumatol, 2009, 28 (6): 639- 646. |
| 33 | Hallowell RW , Danoff SK . Diagnosis and management of myositis-associated lung disease[J]. Chest, 2023, 163 (6): 1476- 1491. |
| 34 | Li L , Wang H , Wang Q , et al. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease[J]. J Neurol Sci, 2019, 397, 123- 128. |
| 35 | Srivastava P , Dwivedi S , Misra R . Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis[J]. Rheumatol Int, 2016, 36 (7): 935- 943. |
| 36 | Li Y , Gao X , Li Y , et al. Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: A series of 474 patients[J]. Front Med (Lausanne), 2020, 7, 363. |
| 37 | Jiang W , Shi JL , Yang HX , et al. Long-term outcomes and prognosis factors in patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies: A single cohort study[J]. Arthritis Care Res (Hoboken), 2023, 75 (5): 1175- 1182. |
| 38 | Komac A , Gokcen N , Yazici A , et al. The role of lactate dehydrogenase-to-albumin ratio in clinical evaluation of adult-onset Still's disease[J]. Int J Clin Pract, 2021, 75 (10): e14615. |
| 39 | Bohan A , Peter JB , Bowman RL , et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis[J]. Medicine (Baltimore), 1977, 56 (4): 255- 286. |
| 40 | Tymms KE , Webb J . Dermatopolymyositis and other connective tissue diseases: A review of 105 cases[J]. J Rheumatol, 1985, 12 (6): 1140- 1148. |
| 41 | Niu Q , Zhao LQ , Ma WL , et al. A new predictive model for the prognosis of MDA5(+) DM-ILD[J]. Front Med (Lausanne), 2022, 9, 908365. |
| 42 | Ding Y , Ge Y . Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome[J]. Ther Adv Chronic Dis, 2022, 13, 20406223221098128. |
| 43 | Chen F , Wang D , Shu X , et al. Anti-MDA5 antibody is associa-ted with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis[J]. Rheumatol Int, 2012, 32 (12): 3909- 3915. |
| 44 | 朱冯赟智, 邢晓燕, 汤晓菲, 等. 肌炎合并血栓栓塞患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2020, 52 (6): 995- 1000. |
| 45 | Davalos D , Akassoglou K . Fibrinogen as a key regulator of inflammation in disease[J]. Semin Immunopathol, 2012, 34 (1): 43- 62. |
/
| 〈 |
|
〉 |